Enliven Therapeutics, Inc (ELVN) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ELVN Hot Sheet
Join SI Premium – FREE
Enliven Therapeutics, Inc (NASDAQ: ELVN) reported Q2 EPS of ($0.49), $0.06 better than the analyst estimate of ($0.55).
For earnings history and earnings-related data on Enliven Therapeutics, Inc (ELVN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ecovyst Inc. (ECVT) Tops Q3 EPS by 2c
- Capital One Financial (COF) call put ratio 1 call to 1.3 puts with a focus on November options
- Myriad Genetics (MYGN) Tops Q3 EPS by 9c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
